Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 1997

View Archived Issues

AHP discloses agents useful for disorders of the dopaminergic system

SmithKline Beecham reports novel hemoregulatory compounds

Novartis discovers compounds with anti-PDE IV and other actions

Agents for BPH claimed by Merck & Co.

MS&D discloses selective 5-HT1D agonists

New antiinflammatory agents from Procter & Gamble

Kotobuki describes new compound with expectorant and antiinflammatory effects

Bioisosteres of sulfonylureas prepared by Belgian investigators

Sanwa Kagaku characterizes analogues of dynemicin A

Potent, selective and orally active ETA antagonist from Zeneca

Royce Laboratories' generic meperidine approved by FDA

New introduction for Ultiva

IVAX's generic estazolam cleared for marketing by FDA

Update on DepoTech's DepoCyt

Outcome in unstable angina improved with ReoPro

Navelbine introduced in the U.K.

First launch for antidepressant from Pharmacia & Upjohn

AIDS vaccine described by Takeda

Fixed-dose losartan/hydrochlorothiazide combination now available in U.K.

Dermatologic and Ophthalmic Drugs Advisory Committee meets July 14-15, 1997

Troponin I inhibits breast cancer growth in preclinical trial

AmBisome NDA to be discussed at Antiviral Drugs Advisory Committee meeting

FDA grants manufacturing approval for bulk ciclosporin

MRC initiates trial to improve survival of patients with resectable NSCLC

QLT PhotoTherapeutics files for Canadian approval of lung cancer treatment

Senetek seeks Danish approval of erectile dysfunction therapy

CarboMed licenses broad-spectrum anticancer agent to Zeneca

Virend superior to placebo for topical treatment of genital herpes in AIDS patients

Epix Medical and Dyax form alliance for the development of novel diagnostics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...